*All times are listed in EDT (UTC-4); all information as of press time*
Chair: Peter Black, Canada
Faculty: Jürgen E. Gschwend, Germany
Shilpa Gupta, United States
Srikala Sridhar, Canada
Tilman Todenhöfer, Germany
At the end of this session, attendees will be able to:
• Review the most updated guidelines on NMBIC and MIBC
• Recognize the importance of risk stratification in the treatment decision-making for NMIBC and MIBC
• Review potential biomarkers to predict response to chemotherapy and immunotherapy in MIBC
• Analyze key data from clinical trials of IO and novel therapies in NMIBC, as well as emerging and combination therapies for MIBC
• Recognize the importance of a multidisciplinary team-based care planning for patients with early stage disease
• Outline immune-related adverse events and best practices for their mitigation and management
0800-0805
Welcome and Introductions
Peter Black
0805-0817
Evolving Treatment of High- Risk NMIBC
Tilman Todenhöfer, Germany
0817-0835
Case Presentation 1: BCG-unresponsive Case
Juergen Gschwend, Germany
0835-0847
New Paradigms in Multimodal Management of MIBC
Srikala Sridhar, Canada
0847-0905
Case Presentation 2: MIBC Case
Shilpa Gupta, United States
0905-0915
Take-Home Messages and Concluding Remarks
Peter Black
This session is supported by SIU Corporate Sponsor Bristol Myers Squibb.
Chair: Lysanne Campeau, Canada
Faculty: Dean Elterman, Canada
Stavros Gravas, Greece
Sender Herschorn, Canada
Case-based Panel Discussion
Dean Elterman, Stavros Gravas, Sender Herschorn
This session is supported by SIU Corporate Sponsor Astellas Pharma.
Co-Chairs: Shusuke Akamatsu, Japan and Marc Dall’Era, United States
Moderator: Marc Dall’Era
At the end of this session, attendees will be able to:
• Recognize when to order genomic testing in prostate cancer treatment
• Determine who is expected to benefit from treatment with PARP inhibitors
• Explain the importance of genetic counseling
• State the current status and future prospect of liquid biopsy
Method: Lectures and discussion
1900–1912
The Role of Genomic Testing in Prostate Cancer
Vito Cucchiara, Italy
1912–1924
DNA Repair Gene Mutations and PARP Inhibitors in Prostate Cancer
Marc Dall’Era
1924–1936
Genetic Counselling in Prostate Cancer
Scott Eggener, United States
1936–1948
Liquid Biopsy in Prostate Cancer, Where Are We Now?
Shusuke Akamatsu
1948–2000
Debate and Q&A on Availability of Genetic Testing and Counselling in Each Region (USA, Italy, and
Japan, each representing North America, Europe and Asia)
All
This session is made possible by an unrestricted educational grant from Takeda Pharmaceutical Company
Chair: Sanjay Kulkarni, India
0600-0605
Introduction
Sanjay Kulkarni, India
0605-0625
Bulbar Urethra Anastomotic, Dorsal and Ventral BMG, Non-Transection Bulbar Urethroplasty
Anthony Mundy, United Kingdom
0625-0645
Posterior Urethral Injury Acute Management and Delayed Treatment, Complex PFUI
Sanjay Kulkarni, India
0645-0658
Penile Urethroplasty
Guido Barbagli, Italy
0658-0700
Take Home Message
Sanjay Kulkarni, India
This session is made possible by an unrestricted educational grant provided from Sun Pharma.
Chair: David Ralph,United Kingdom
At the conclusion of this activity, participants will be able
to:
• Consistently identify the best candidates for IPP
• Provide preoperative patient support and management that will optimize the likelihood that patients will be satisfied with their procedure
• Provide postoperative support that addresses common patient concerns and quickly identifies and manages complications, should they arise
• Keep your clinic running safely in the era of COVID-19
Panelists
Sebastien Beley, France
Tobias Kohler, United States
Koenraad van Renterghem, Belgium
Javier Romero-Otero, Spain
This session is supported by SIU Corporate Sponsor Coloplast.
Chair: Shaheen Alanee, United States
At the end of this session, attendees will be able to:
• Recognize the role of the multidisciplinary team (MDT) approach in the patient journey through treatment with immunotherapy for advanced bladder cancer
• Receive an introduction to systemic Immunotherapy in bladder cancer, Role of the MDT in identifying and managing immune-related side effects associated with anti-PD1 agents
• Understand the importance of interdisciplinary communication and education in preventing life-threatening complications
Method: Lectures and discussion
1400–1405
Course Introduction
Shaheen Alanee
1405–1425
Background on Bladder Cancer and Introduction to Anti-PD1 Agents
Shaheen Alanee
1425–1505
Benefits of MDT Approach for Patients Receiving Treatment with Anti PD Agents, and the Role of Anti-PD1 Agents in the Management of Locally Advanced and Metastatic Bladder Cancer
Petros Grivas, United States
1505–1530
Group Discussion
This session is made possible by an unrestricted educational grant from AstraZeneca.
